NeoGenomics

NEOPre-clinical

NeoGenomics is a publicly-traded leader in cancer diagnostics, founded in 1999, with a mission to save lives by improving patient care through precision oncology testing. The company leverages one of the largest oncology databases, with over 2 million unique patient profiles, to deliver more than 1.7 million tests annually to over 4,400 medical sites. Its strategic focus encompasses three core pillars: providing advanced testing solutions to healthcare providers, accelerating drug development for biopharma partners, and harnessing real-world data to advance personalized medicine.

Market Cap

$972.3M

Employees

2,200

Focus

DiagnosticsGenetics & Genomics

NEO · Stock Price

USD 7.49+4.04 (+117.10%)

Historical price data

AI Company Overview

Technology Platform

Integrated multi-modal cancer diagnostics platform encompassing next-generation sequencing (NGS), immunohistochemistry, flow cytometry, FISH, and liquid biopsy, coupled with a proprietary real-world oncology database containing over 2 million patient profiles for data-driven insights.

Funding History

Total raised: $105M

PIPE$100MUndisclosedMay 15, 2020

IPOUndisclosedUndisclosedOct 28, 2011

Series A$5MUndisclosedJun 15, 2001

SeedUndisclosedUndisclosedJun 15, 1999

Opportunities

Significant growth opportunities exist in the expanding MRD testing market, where RaDaR® ST can become a standard of care.

Monetizing the large-scale real-world oncology database through partnerships with biopharma for drug development and with payers for outcomes analysis represents a high-margin adjacent revenue stream.

Continued penetration into the large community oncology market and international expansion also offer avenues for growth.

Risk Factors

Key risks include reimbursement challenges from payers for advanced diagnostics, intense competition from both specialized and large-scale lab companies, increasing regulatory scrutiny of laboratory-developed tests (LDTs), and the commercial execution risk associated with scaling adoption of newer platforms like RaDaR.

Competitive Landscape

NeoGenomics competes with leaders in genomic profiling (Foundation Medicine/Roche), liquid biopsy (Guardant Health), and large national labs (Quest, LabCorp). Its differentiation lies in its comprehensive, multi-modal testing menu (including strong hematology focus), its scale of over 1.7 million tests annually, and its unique asset of a large, proprietary oncology database used to generate real-world evidence.

Publications

Patents